Fumarate therapies are equally effective among Black, Hispanic, Asian, and white people with relapsing forms of MS, a real-world study shows.

Fenebrutinib significantly reduced new lesions with active inflammation in people with relapsing MS in a Phase 2 trial.

Columnist Ahna Crum, who's a practitioner in functional medicine, questioned herself when she had an unexpected MS relapse.